Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
chronic kidney disease
Biotech
Novo Nordisk discards $1.3B kidney drug in wake of phase 3 fail
Novo Nordisk, after mulling the implications of a phase 3 fail, has given up on a late-stage kidney drug acquired in a $1.3 billion deal.
James Waldron
Nov 6, 2024 4:54am
Otsuka's kidney disease drug improves UPCR levels in ph. 3 trial
Oct 22, 2024 10:38am
ProKidney halts ph. 3 trial not needed for cell therapy approval
Sep 3, 2024 8:55am
Pathalys raises $105M to prepare kidney disease drug for FDA
Aug 20, 2024 10:00am
Novo's Kerendia challenger falls flat in phase 3
Jun 26, 2024 1:39pm
Baxter study shows expanded dialysis can lower death rates
May 30, 2024 2:06pm
